RxDoctor Payments DataLook up a doctor →

Yelena Novik, MD

Hematology & Oncology · New York, NYNPI 1710988738

Payments from drug & device makers

$3,118,462in general payments, 2019–2025

Across 252 payments — averaging $12,375 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2.2M
  • Astellas Pharma Global Development$319K
  • Gilead$191K
  • Radius Health, Inc.$161K
  • Sanofi US Services Inc.$128K
  • Macrogenics, Inc.$56K
  • plus $110K from 7 others
$1,507in research payments, 2019–2025

Across 2 payments — averaging $753.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astellas Pharma Global Development$2K

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,118,462 in reported general payments places this provider in the 95th percentile of 967 hematology & oncology providers in New York.

See all hematology & oncology providers in New York

Medicare billing

Part B allowed, 2024
$55,040
Medicare patients
280
Services billed
547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →